Navigation Links
Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control (APIC) Annual Conference
Date:6/4/2009

SUNNYVALE, Calif., June 4 /PRNewswire-FirstCall/ --- Cepheid (Nasdaq: CPHD) today announced speaker and program highlights for its symposium, "On-Demand HAI Testing: Good Medicine and Good Business," which the company will host at the 2009 Association for Professionals in Infection Control (APIC) annual conference, taking place in Fort Lauderdale, Florida, June 7th - 10th. Cepheid's GeneXpert(R) Systems and menu of molecular diagnostic tests will be on display in booth #906 on the exhibition floor.

"Management and prevention of Healthcare Associated Infections (HAIs) is a shared responsibility that includes the entire healthcare industry," said Sandra Finley, Cepheid's Vice President of Marketing. "We are pleased to present industry experts who will discuss the importance of reducing and eliminating HAI infections and the operational benefits that these investments bring in quality improvements, patient outcomes, and hospital throughput efficiencies."

The symposium, "On-Demand HAI Testing: Good Medicine and Good Business," is scheduled for Wednesday, June 10, 2009 from 11:30 a.m. to 1:30 p.m. EST. Interested parties, unable to attend the APIC conference, are invited to listen to the event live via webcast. To access the live webcast, please register through Cepheid's website at www.cepheid.com/events at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software. APIC attendees can register to attend this exhibitor-sponsored symposium while at the conference.

The scheduled presenters are:

    Jorge P. Parada, MD, MPH
    Associate Professor
    Medical Director Infection Control Program
    Researcher Associate, Infectious Diseases and Immunology Institute (inDII)
    Stritch School of Medicine Loyola University Chicago

    William J. Ward, Jr., MBA
    Associate Professor
    Director, MHS Degree in Health Finance and Management
    Sommer Scholars Program Faculty Director
    Johns Hopkins Bloomberg School of Public Health

    Fred C. Tenover, Ph.D., D (ABMM)
    Senior Director, Scientific Affairs, Cepheid
    Adjunct Professor of Epidemiology, Rollins School
    of Public Health, Emory University, Atlanta, GA

Healthcare-associated infections exact a significant toll on human life, and are among the top ten leading causes of death in the United States. Recent reports estimate hospital stays for Methicillin-resistant Staphylococcus aureus (MRSA) infection have more than tripled since 2000 and represent $20 billion in excess healthcare costs each year. Similarly, Clostridium difficile infections have been increasing in incidence and severity, and have become a substantive and growing burden in hospitalized patients, prompting the need for earlier and accurate detection.

About Cepheid

Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See http://www.cepheid.com for more information.

    CONTACTS:
    For Media Inquiries:                   For Cepheid Investor Inquiries:
    --------------------                   -------------------------------
    Jared Tipton                           Jacquie Ross
    Cepheid Corporate Communications       Cepheid Investor Relations
    408-400-8377                           408-400-8329
    jared.tipton@cepheid.com               investor.relations@cepheid.com


'/>"/>
SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cepheid to Present at ThinkEquity Partners 5th Annual Growth Conference
2. Cepheid Schedules Teleconference and Webcast for Third Quarter 2007 Results
3. Cepheid and Broadlane Sign Group Purchasing Contract for GeneXpert(R) Systems and Xpert(TM) Molecular Diagnostic Tests, Including Xpert MRSA
4. Cepheid to Present at the Needham Tenth Annual Growth Stock Conference
5. Cepheid Comments on Study Regarding MRSA Surveillance Reported in the Journal of the American Medical Association
6. Cepheid Selected as Vendor of Choice by Connecticut Hospital Association Shared Services Program for Molecular MRSA Surveillance Testing
7. Cepheid Reports Record Revenue of $44.8 Million
8. Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations
9. Cepheid Launches First On-Demand Molecular Diagnostic Test for Clostridium Difficile Into European Market
10. Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections
11. Cepheid Reports Fourth Quarter and Full Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... An April 24th article on Yahoo! ... 180 pounds with the help of a weight loss surgery. The woman, declaring “I will ... that have been left following her dramatic weight loss. Dr. Feiz & Associates notes that, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Somnoware, a leading provider ... Online(TM), which enables sleep physicians to create and edit their interpretation reports. This ... provides a familiar interface that does not require additional training to use. It ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, ... the GlycoMark test throughout the Northeast U.S. , GlycoMark is the only ... The GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic ... has joined the revolutionary endoscopic practice under Dr. Datta. Patel is a Board ... Medicine. The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is ...
(Date:4/28/2017)... Ca (PRWEB) , ... April 28, 2017 , ... ... cardiac or hERG liability could substantially improve drug safety and minimize the cost ... provided for validating ion channel inhibition using cell lines and for cardiac toxicity ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... The Mobile X-Ray product segment is the most attractive market ... period Mobile X-Ray segment is the largest segment ... market, which is estimated to be valued at more than ... 7% over the forecast period. Mobile X-Ray segment is expected ... Mn in 2017 over 2016. The segment,s revenue in the ...
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
Breaking Medicine Technology: